Menopause: The Journal of The North American Menopause Society最新文献

{"title":"Masturbation frequency and experiences among US women aged 40-65 years: comparisons across different stages of the menopause transition.","authors":"Cynthia A Graham, Louise Ferrall, Justin J Lehmiller","doi":"10.1097/GME.0000000000002597","DOIUrl":"10.1097/GME.0000000000002597","url":null,"abstract":"<p><strong>Objective: </strong>The aims of the study were to assess the reported frequency of, and reasons for, masturbation and experiences of orgasm and sex toy use during masturbation and to compare these experiences across women at different stages of the menopause transition.</p><p><strong>Methods: </strong>A nationally representative US sample of 1,500 women aged 40-65 (M age: 52.5 y) completed an online survey asking about their experiences during masturbation. Data were analyzed using descriptive statistics, χ 2 tests, and ANOVAs.</p><p><strong>Results: </strong>Over half (55.8%) of the sample described themselves as postmenopausal, 22.7% as perimenopausal, and 21.5% as premenopausal. There were significant differences in the frequency of masturbation, with postmenopausal women reporting a lower frequency compared with the other 2 groups ( P < 0.014). Postmenopausal women also rated the importance of masturbation in their lives as lower compared with perimenopausal and premenopausal women ( P < 0.001). There were no group differences in the frequency of orgasm during masturbation, with women reporting orgasm an average of 81% of the times that they masturbated. Overall, more women reported that the quality of their orgasms had gotten better than worse over the last 10 years, and most noticed no change. More women reported that orgasm had become more difficult to attain, but about half had noticed no change. There were no significant group differences in the percentage of times that sex toys were used during masturbation (44.4% for the total sample).</p><p><strong>Conclusions: </strong>Sexual pleasure and orgasm remain important for many older women and menopause is not always associated with adverse changes in sexuality, including the ability to orgasm during masturbation.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"903-912"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transdermal versus oral hormone therapy in premature ovarian insufficiency.","authors":"Klara Beitl, Katalin Widmann, Rodrig Marculescu, Robert Krysiak, Johannes Ott","doi":"10.1097/GME.0000000000002588","DOIUrl":"10.1097/GME.0000000000002588","url":null,"abstract":"<p><strong>Objectives: </strong>Hormone therapy is recommended in women with premature ovarian insufficiency to mitigate long-term risks associated with estrogen deficiency, such as loss of bone mineral density. However, data on the optimal route of administration are scarce. This study aimed to compare the effect of transdermal and oral hormone therapies on the T-scores of the femur and the hip in women with premature ovarian insufficiency.</p><p><strong>Methods: </strong>This retrospective, single-center cohort study included 55 women with spontaneous premature ovarian insufficiency who were regularly monitored at the Clinical Division of Gynecological Endocrinology and Reproductive Medicine of the Medical University of Vienna. For hormone therapy, participants received either oral or transdermal estrogen therapy. The main outcome parameters were the T-scores of the femur and hip assessed by dual-energy x-ray absorptiometry scans.</p><p><strong>Results: </strong>Among the 55 women included [median age: 34 y, interquartile range (IQR): 27-36], 65.5% showed reduced bone mineral density in the dual-energy x-ray absorptiometry scan results (osteopenia: n= 27, 49.1%; osteoporosis: n= 9, 16.4%). Participants were treated with transdermal and oral estradiol in 27 (49.1%) and 28 cases (50.9%), respectively. There were no significant differences in the T-scores of the femur and the hip, neither at baseline ( P =0.586, P =0.400) nor at follow-up assessment ( P =0.618, P =0.471) between the two treatment groups.</p><p><strong>Conclusions: </strong>Both oral and transdermal hormone therapies effectively help maintain bone mineral density in women with premature ovarian insufficiency, indicating that either option is a suitable treatment choice for this population.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"913-919"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prioritizing and optimizing bone health in premature ovarian insufficiency.","authors":"Raja A Sayegh","doi":"10.1097/GME.0000000000002652","DOIUrl":"10.1097/GME.0000000000002652","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":"901-902"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To the editor.","authors":"Anne Armstrong, Rebecca Bowen, Paula Briggs, Carlo Palmieri, Annice Mukherjee, Kathryn Williams","doi":"10.1097/GME.0000000000002669","DOIUrl":"10.1097/GME.0000000000002669","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":"32 10","pages":"983-984"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of progestogens in hormone therapy.","authors":"James H Liu","doi":"10.1097/GME.0000000000002649","DOIUrl":"10.1097/GME.0000000000002649","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":"32 10","pages":"975-977"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopausal hormone therapy for breast cancer patients: what is the current evidence?","authors":"Sarah Glynne, James Simon, Anthony Branson, Stephen Payne, Louise Newson, Isaac Manyonda, Susan Cleator, Michael Douek, Sasha Usiskin, Jeffrey S Tobias, Jayant S Vaidya","doi":"10.1097/GME.0000000000002627","DOIUrl":"https://doi.org/10.1097/GME.0000000000002627","url":null,"abstract":"<p><strong>Importance and objectives: </strong>Many breast cancer survivors struggle with menopausal symptoms due to oncological treatment-induced hormone deficiency, or because they experience menopause some years after completing treatment, but have limited menopause treatment options. Estrogen replacement therapy is the most effective treatment for menopausal symptoms, but is not recommended after breast cancer because it can increase the risk of relapse. Our objectives were to review the evidence and develop a consensus statement to define the role of menopausal hormone therapy after breast cancer, and to highlight evidence gaps to inform future research.</p><p><strong>Methods: </strong>A 25-member multidisciplinary panel developed the consensus statements using a modified Delphi methodology. The panel consisted of 18 senior doctors who voted (5 GP menopause specialists, 5 gynecologists, 4 medical oncologists, 3 breast surgical oncologists, and 1 breast radiologist), and 7 members who did not vote (4 patient representatives, 1 medical oncologist, 1 urologist and 1 administrator). Consensus was defined as ≥70% agreement with low-to-moderate variation in extent of agreement (mean absolute deviation from median of ≤0.75). We reviewed current evidence relating to use of vaginal and systemic menopausal hormone therapy (\"MHT\", also known as \"hormone therapy,\" \"HT\" or \"hormone replacement therapy,\" \"HRT\") after breast cancer diagnosis, and adjuvant endocrine (anti-estrogen) therapy, and developed a narrative synthesis. Finally, four additional breast cancer specialists peer-reviewed the manuscript.</p><p><strong>Discussion and conclusions: </strong>The panel agreed that some women may choose to take MHT, (off-label use) and accept an increased risk of relapse in exchange for relief from menopausal symptoms and an improved quality of life, and that preferences may vary according to individual circumstances and the absolute risk of relapse. All respondents agreed or strongly agreed with statements supporting shared decision making and individualized menopause care (MADM 0.29).In our review of the literature, we found mainly moderate quality evidence concerning use of vaginal and systemic estrogen after breast cancer, and high quality evidence concerning the benefits of anti-estrogen therapy for estrogen receptor positive breast cancer. Based on the available data, we recommend that shared decisions are based on (1) an individual's menopausal symptoms and impact on quality of life, (2) the potential increase in an individual's risk of relapse by use of menopausal hormone therapy, and (3) patient preferences, views and treatment goals. Clinicians and patients can use our findings to make informed menopause treatment choices after breast cancer. We strongly recommend registering all patients considering MHT after breast cancer in a clinical study (eg, MENopausal hormone therapy and Outcomes After Breast Cancer, the MENO-ABC trial).</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To the Editor.","authors":"Rüyam Ercenk, İbrahim Karaca","doi":"10.1097/GME.0000000000002673","DOIUrl":"https://doi.org/10.1097/GME.0000000000002673","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In reply.","authors":"Darren Yuen Zhang Tan, Beverly Wen Xin Wong, Liang Shen, Ling-Jun Li, Eu-Leong Yong","doi":"10.1097/GME.0000000000002674","DOIUrl":"https://doi.org/10.1097/GME.0000000000002674","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Life's Crucial 9 with self-reported reproductive lifespan and pregnancy loss: the National Health and Nutrition Examination Survey 2007-2018.","authors":"Yaru Ju, Hongbin Wang, Yanjing Yang, Xiaolin Hou, Yage Wang, Xiaofeng Zhang, Yan Feng","doi":"10.1097/GME.0000000000002628","DOIUrl":"https://doi.org/10.1097/GME.0000000000002628","url":null,"abstract":"<p><strong>Objectives: </strong>This study explores the relationship between Life's Crucial 9 (LC9), a recently updated cardiovascular health (CVH) assessment tool by the American Heart Association (AHA), and self-reported reproductive lifespan, as well as pregnancy loss history.</p><p><strong>Methods: </strong>The analysis utilized data from 2,405 postmenopausal women in the United States collected from the National Health and Nutrition Examination Survey (NHANES) database between 2007 and 2018. LC9 scores, ranging from 0 to 100, were calculated based on AHA's definitions and divided into health behavior and health factor components. The association between LC9 scores, reproductive lifespan, and the self-reported incidence of pregnancy loss was evaluated using weighted multivariable linear and Poisson regression models.</p><p><strong>Results: </strong>Individuals in the highest tertile of the LC9 score experienced a significantly higher age at menopause (0.034 y, [0.009, 0.059)]) and a longer reproductive lifespan (0.045 y, [0.004, 0.085]) compared with those in the lowest tertile. Furthermore, we identified a linear association between the LC9 score and reproductive lifespan. The positive correlation between the LC9 score and reproductive lifespan was notably stronger among non-Hispanic Whites. For self-reported pregnancy loss, the fully adjusted relative prevalence (95% CI) for the LC9 score was 0.699 (0.436-1.120), which remained consistent after further adjustment for reproductive lifespan. However, this association did not reach statistical significance, indicating that there may not be a strong relationship between LC9 scores and pregnancy loss in this cohort.</p><p><strong>Conclusions: </strong>Our study indicated that a higher LC9 score could potentially extend women's reproductive lifespan and enhance reproductive health, although no significant association was found with pregnancy loss in this population.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Documentation of menopause-related international classification of diseases codes in the electronic health record in midlife women with menopause symptoms.","authors":"Jana Karam, Nancy Safwan, Rickey E Carter, Joshua Pevnick, Carl Berdahl, Rajeev Chaudhry, Juliana M Kling, Ekta Kapoor, Stacey J Winham, Kristin Cole, Stephanie S Faubion, Chrisandra L Shufelt","doi":"10.1097/GME.0000000000002648","DOIUrl":"https://doi.org/10.1097/GME.0000000000002648","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the documentation of menopause-related International Classification of Diseases-10 (ICD-10) codes in the electronic health record (EHR) among midlife women with moderate or greater menopause symptoms receiving primary care.</p><p><strong>Methods: </strong>This cross-sectional study from the Hormones and Experiences of Aging (HERA) cohort included women aged 45-60 years receiving primary care at one of 4 Mayo Clinic sites who completed a one-time survey between March 1, 2021 and June 30, 2021. The survey captured demographic data, menopause symptoms using the Menopause Rating Scale (MRS), health care utilization, and treatment. Women with an MRS score ≥12 were included. The primary outcome was documentation of a menopause-related ICD-10 code in the EHR in the 12 months before survey completion.</p><p><strong>Results: </strong>Of 5,254 women with completed surveys, 2,414 (49%) had an MRS score ≥12 and were included. Among these, 1,519 (63%) reported seeking care for their menopause symptoms in the past 12 months, but only 345 (23%) had a menopause-related ICD-10 code. Women with an ICD-10 code had higher MRS scores (18 [IQR: 14-22] vs 17 [IQR: 14-20]; P = 0.002) and were more likely to use systemic hormone therapy (HT; 26% vs 9%; P < 0.001), and vaginal HT (20% vs 6%; P < 0.001).</p><p><strong>Conclusions: </strong>Menopause-related ICD-10 diagnosis codes were under-documented in women with significant menopause symptom burden. Those with a code were more likely to report menopause treatment. These findings highlight a critical gap between symptom burden and diagnosis coding in the EHR, underscoring the need to improve identification and management of menopause symptoms.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}